|Bid||0.00 x 900|
|Ask||0.00 x 1200|
|Day's Range||75.14 - 76.29|
|52 Week Range||64.27 - 89.54|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||45.17|
|Earnings Date||Oct 25, 2018|
|Forward Dividend & Yield||2.28 (3.13%)|
|1y Target Est||87.91|
This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.
Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.
Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.
just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.
Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.
Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.
Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene.
In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.
Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.
As the market fell sharply Thursday, this biotech boomed after raising $324 million in an initial public offering.
Gilead Sciences, Inc. (GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2018 and provide a general business update. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 1789278 to access the call.
-- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect Ongoing Commitment to Advancing the Care of People with Liver Disease--
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.
How far off is Gilead Sciences Inc (NASDAQ:GILD) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...
In October, of the 28 analysts covering Gilead Sciences (GILD), 18 analysts gave the stock a “buy” or higher rating, while ten analysts gave the stock a “hold” rating. The mean rating for Gilead Sciences stock is 2.14 with a target price of $87.96, which implies an upside potential of 14.9% over the company’s closing price of $76.56 on October 4.
Gilead Sciences’ (GILD) selling, general, and administrative expenses increased from $897.0 million in the second quarter of 2017 to $980.0 million in the second quarter. The increase was due to higher stock-based compensation expenses and costs after the Kite acquisition.
Cara Therapeutics (CARA) is a clinical-stage biotechnology company that develops new chemical entities for managing pain and pruritus. It reported EPS of -$0.52 on revenues of $2.87 million in the second quarter.
Gilead Sciences (GILD) generated total revenues of $5.65 billion in the second quarter—compared to $7.14 billion in the second quarter of 2017. The company generates revenues from sales of products and royalties and contract arrangements. Gilead Sciences’ product sales decreased from $7.05 billion in the second quarter of 2017 to $5.54 billion in the second quarter. The company’s royalty, contract, and other revenues increased from $95.0 million in the second quarter of 2017 to $108.0 million in the second quarter.
On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating the safety and efficacy of Biktarvy for treating HIV-1 infections in treatment-naive patients. The drug was found to be statistically non-inferior to a regimen of abacavir, dolutegravir, and lamivudine through 96 weeks of therapy.